Suven Life Sciences Completes Phase 2b Enrollment for Novel Depression Drug Ropanicant Two Months Ahead of Schedule
Key Insights
Suven Life Sciences achieved 100% patient enrollment in its Phase 2b trial of Ropanicant for major depressive disorder (search), completing recruitment of 195 patients more than two months ahead of schedule.
The randomized, double-blind, placebo-controlled trial is evaluating the nicotinic α4β2 receptor (search) antagonist across 35 US sites over six weeks of treatment.
Safety monitoring has shown no significant concerns to date, with topline efficacy and safety results expected by May 2026.
Suven Life Sciences Limited has successfully completed patient enrollment in its Phase 2b clinical trial of Ropanicant for major depressive disorder (search) (MDD (search)), achieving the 100% enrollment milestone more than two months ahead of schedule. The clinical-stage biopharmaceutical company, which focuses on developing innovative treatments for central nervous system disorders, reached its target of 195 patients for randomization in less than six months from study initiation.
Trial Design and Scope
The Phase 2b study is a randomized, double-blind, placebo-controlled trial conducted exclusively across 35 sites in the United States. The six-week treatment duration trial will evaluate the efficacy and safety of Ropanicant, a nicotinic α4β2 receptor (search) antagonist, compared to placebo in improving symptoms of depression as measured by the Montgomery-Asberg Depression Rating Scale (MADRS).
The rapid pace of recruitment underscores strong engagement from both investigators and participating patients, reflecting significant interest in this potential treatment option with a novel mechanism of action for depression.
Safety Profile and Timeline
Safety data from the study is being monitored continuously, with no significant concerns observed to date. The company anticipates presenting topline efficacy and safety results by May 2026.
"I am deeply grateful to the patients, caregivers, investigators, and our clinical development team for their exceptional commitment in helping us achieve this milestone so rapidly," said Venkat Jasti, Chairman and Managing Director of Suven Life Sciences. "Together, we are advancing an important scientific effort to evaluate the potential of Ropanicant in patients with MDD (search). This collective progress moves us closer to delivering new therapeutic options that can meaningfully improve patient lives."
Clinical Significance
Dr. Ramakrishna Nirogi, President and Chief Scientific Officer of Suven Life Sciences, emphasized the potential impact of the research. "Today's milestone represents another exciting step forward as we advance the investigation of Ropanicant in patients with MDD (search)," he said. "If positive, ropanicant has a potential to transform the lives of people affected by MDD and those around them."
The successful enrollment ahead of schedule demonstrates the high level of interest from both the medical community and patients in exploring new therapeutic approaches for major depressive disorder (search) through this novel nicotinic receptor antagonist mechanism.